Phosphorylated neuronal @entity842 synthase in @entity9 in XXXX .

@entity8561 @entity71541 @entity66 @entity26 @entity3733 @entity14374 @entity842 @entity158 @entity35 @entity9 @entity5612
@entity9 caused by nervous system @entity66 . The pathogenesis and the mechanism underlying @entity9 remains unclear. The only known neurobiological component involved in the @entity9 is @entity842 (NO). NO is synthesized by @entity842 synthase ( @entity5612 ) from @entity8561 and @entity26 . @entity5612 is involved in the @entity158 and @entity9 . In this study, we aimed to identify whether @entity14374 reduced the @entity158 in the @entity35 . Sixty adult male SD @entity35 were randomly divided into 4 groups. Sham group and model group were not received treatment. Experimental group received intrathecal injection of @entity14374 , and negative control group received @entity3733 injection 30 min before @entity158 test. After last test of @entity158 threshold, the @entity35 were sacrificed and lumbar spinal tissues were sampled for analysis of the expression of pnNOS and pCaMK II by quantitative PCR and Western blotting. @entity158 threshold was increased in the @entity35 received @entity14374 treatment (P<0.01), and the expression levels of pnNOS was increased (P<0.05) in experimental group and accompanied with decrease of CaMK II expression (P<0.05). By administration of @entity14374 , the interaction of @entity5612 and the adaptor protein @entity71541 was reduced through inhibition of CaMK II by @entity14374 . In conclusion, this study reveals that @entity14374 can reduce @entity9 via inhibiting the activity of CaMK II, and then increase the level of phosphorylated @entity5612 , to reduce the interaction with @entity71541 .
